Gufic Biosciences Q2 FY27 Results Preview: Date, Trend and Outlook

Gufic Biosciences CMP Rs 425.50. Q1 FY27 (Jun26) revenue Rs 261 Cr, net profit Rs 22 Cr, OPM 18.01%. Results date not yet announced.

Updated: 18 Sept 2026 • 9:57 am

Posted by:

Gufic Biosciences Q2 FY27 Results Preview: Date, Trend and Outlook

The Gufic Biosciences Q2 results are on the horizon for this pharmaceutical formulations company, with the September 2026 quarter numbers likely to be announced in late October or early November 2026 based on the company's past filing pattern, though no official date has been confirmed yet. Anyone following the Gufic Biosciences Q2 results closely should wait for the formal board meeting intimation rather than relying on unverified dates. Track the latest Gufic Biosciences share price on Univest as the results date nears.

Open a free demat account with Univest to follow Gufic Biosciences ahead of results

Table of Contents

What to Expect From the Gufic Biosciences Q2 Results

Without any published analyst estimate for the September 2026 quarter, expectations for the Gufic Biosciences Q2 results have to be built from the trend already visible in the last five quarters. Revenue has climbed steadily from Rs 224 Cr in June 2025 to Rs 261 Cr in June 2026, and operating margin has improved from 15 percent to 18.01 percent over the same period. That consistent direction is the main qualitative signal going into the Gufic Biosciences Q2 results, rather than any specific number.

Net profit has also trended higher, moving from Rs 13 Cr to Rs 22 Cr across the five quarters shown, with the most recent two quarters both landing at Rs 22 Cr. Whether that plateau continues or extends further will be a key theme investors watch in the Gufic Biosciences Q2 results.

Also read – Premier Energies Q2 Results FY27 Preview

Previous Quarter: Q1 FY27 (June 2026) Actuals

In the quarter ended June 2026, Gufic Biosciences Ltd. reported revenue of Rs 261 Cr, operating profit of Rs 47 Cr and an operating margin of 18.01 percent, its second-highest margin print in five quarters. Net profit stood at Rs 22 Cr, matching the March 2026 quarter and marking the strongest sustained profitability run for the company on record among the data available ahead of the Gufic Biosciences Q2 results.

Base Quarter: Q2 FY26 (September 2025)

The year-ago quarter the Gufic Biosciences Q2 results will be measured against is September 2025, when Gufic Biosciences posted revenue of Rs 237 Cr, operating profit of Rs 38 Cr, an operating margin of 16 percent and net profit of Rs 17 Cr.

Five-Quarter Trend

Quarter	Revenue (Rs Cr)	OPM	Net Profit (Rs Cr)
Jun 2025	224	15.00%	13
Sep 2025	237	16.00%	17
Dec 2025	231	14.29%	12
Mar 2026	252	18.65%	22
Jun 2026	261	18.01%	22

The pattern across these five quarters is one of steady, profitable growth with margin improving overall despite a dip in December 2025. This consistency is the strongest backdrop any company preview can offer ahead of the Gufic Biosciences Q2 results.

Track Gufic Biosciences and open your free demat account on Univest

Key Factors to Watch

Also read – Indiamart Intermesh Q2 Results FY27 Preview

Export demand for injectable and critical care formulations, capacity utilisation at newer facilities, and raw material cost trends will all influence how the Gufic Biosciences Q2 results eventually shapes up. Continued momentum in the specialty and hospital-focused product mix is another factor worth tracking.

Valuation Snapshot

At Rs 425.50, Gufic Biosciences Ltd. trades at a trailing PE of about 58.27, a price-to-book ratio of 6.42 and a return on equity of 10.1 percent. The 52-week range is Rs 268 to Rs 467.80, and the stock trades above both its 50-day and 200-day moving averages, with a modest dividend yield of 0.02 percent.

Get started on Univest and open your demat account before the results season

What to Watch Around the Gufic Biosciences Q2 Results

The board meeting intimation for the Gufic Biosciences Q2 results, once filed, will confirm the exact date. Beyond that, whether operating margin can hold near the 18 percent level achieved in the last two quarters is the central question for the Gufic Biosciences Q2 results.

Conclusion

The steady, profitable trend across the last five quarters gives Gufic Biosciences Ltd. a reasonably stable backdrop heading into its September 2026 results. The Gufic Biosciences Q2 results will confirm whether this improving margin and profit trajectory continues, and investors should wait for the official announcement rather than acting on speculation around the Gufic Biosciences Q2 results.

Disclaimer: Univest Securities Private Limited is a SEBI-registered Research Analyst (Registration No. INH000013776). The content above is for educational and informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. All figures are drawn from historical, publicly disclosed quarterly financials and current market data; no specific Q2 FY27 results, estimates, or forecasts are implied. Please consult a SEBI-registered investment adviser and verify all data independently before making any investment decision.

When will Gufic Biosciences announce its Q2 FY27 results?

Gufic Biosciences Ltd. has not officially confirmed its Q2 FY27 results date. Based on its historical pattern, the announcement is expected in late October or early November 2026.

What was Gufic Biosciences' net profit in the previous quarter?

In Q1 FY27 (June 2026), Gufic Biosciences Ltd. reported a net profit of Rs 22 Cr on revenue of Rs 261 Cr, with an operating margin of 18.01 percent.

Has Gufic Biosciences' margin been improving?

Yes, Gufic Biosciences' operating margin has moved from 15 percent in June 2025 to 18.01 percent in June 2026, showing a broadly improving trend across the last five quarters.

What is Gufic Biosciences' current valuation?

Gufic Biosciences shares trade around Rs 425.50, with a trailing PE of about 58.27, a price-to-book ratio of 6.42 and a return on equity of 10.1 percent.